{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:34:48Z","timestamp":1789011288696,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41375-020-0948-0","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T14:04:06Z","timestamp":1595340246000},"page":"1134-1144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4000-6904","authenticated-orcid":false,"given":"Marc-Andrea","family":"Baertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Schlenzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Habermehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Steffen","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Luntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Goerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schmidt-Hieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullrich","family":"Graeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Haenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W.","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Noppeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the German Myeloma Multicenter Group (GMMG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"948_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3324\/haematol.2017.174573","volume":"103","author":"F Gay","year":"2017","unstructured":"Gay F, Engelhardt M, Terpos E, W\u00e4sch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. Haematologica. 2017;103:197-211.","journal-title":"Haematologica"},{"key":"948_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","volume":"15","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. Multiple myeloma, version 3.2017, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2017;15:230\u201369.","journal-title":"J Natl Compr Canc Netw"},{"key":"948_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med. 1996;335:91\u20137.","journal-title":"N Engl J Med"},{"key":"948_CR4","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875\u201383.","journal-title":"N Engl J Med"},{"key":"948_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"948_CR6","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1200\/JCO.2016.34.15_suppl.8000","volume":"34","author":"M Cavo","year":"2016","unstructured":"Cavo M, Palumbo Antonio, Zweegman Sonja, Dimopoulos Meletios A, Hajek Roman, Pantani Lucia, et al. Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial). J Clin Oncol. 2016;34:8000-8000.","journal-title":"J Clin Oncol."},{"key":"948_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bjh.12579","volume":"163","author":"D Atanackovic","year":"2013","unstructured":"Atanackovic D, Schilling G. Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol. 2013;163:565\u201372.","journal-title":"Br J Haematol"},{"key":"948_CR8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"G Cook","year":"2014","unstructured":"Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label. Lancet Oncol. 2014;15:874\u201385.","journal-title":"Lancet Oncol"},{"key":"948_CR9","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","volume":"3","author":"G Cook","year":"2016","unstructured":"Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340\u201351.","journal-title":"Lancet Haematol"},{"key":"948_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2321-2","volume":"16","author":"M-A Baertsch","year":"2016","unstructured":"Baertsch M-A, Schlenzka J, Mai EK, Merz M, Hillenga\u00df J, Raab MS, et al. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide\/dexamethasone versus lenalidomide\/dexamethasone plus subsequent autologous stem cell transplantatio. BMC Cancer. 2016;16:290.","journal-title":"BMC Cancer"},{"key":"948_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"948_CR12","doi-asserted-by":"publisher","unstructured":"Baertsch M-A, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, et al. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: a subgroup analysis from the phase III trial ReLApsE. Eur J Haematol. 2017;99. https:\/\/doi.org\/10.1111\/ejh.12888.","DOI":"10.1111\/ejh.12888"},{"key":"948_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115\u201323.","journal-title":"Br J Haematol"},{"key":"948_CR14","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl J Med. 2003;348:2609\u201317.","journal-title":"N. Engl J Med"},{"key":"948_CR15","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","volume":"95","author":"K Neben","year":"2010","unstructured":"Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95:1150\u20137.","journal-title":"Haematologica"},{"key":"948_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat softw. 2011;45:1\u201367.","journal-title":"J Stat softw"},{"key":"948_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133\u201342.","journal-title":"N Engl J Med"},{"key":"948_CR18","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau J-L, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123\u201332.","journal-title":"N Engl J Med"},{"key":"948_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","volume":"82","author":"EA Stadtmauer","year":"2009","unstructured":"Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82:426\u201332.","journal-title":"Eur J Haematol"},{"key":"948_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29\u201337.","journal-title":"Lancet Oncol"},{"key":"948_CR21","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet. 2007;370:1209\u201318.","journal-title":"Lancet"},{"key":"948_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319\u201331.","journal-title":"N Engl J Med"},{"key":"948_CR23","first-page":"141206080130007","volume":"372","author":"AK Stewart","year":"2014","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2014;372:141206080130007.","journal-title":"N Engl J Med"},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"N Engl J Med"},{"key":"948_CR25","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782\u201391.","journal-title":"N Engl J Med"},{"key":"948_CR27","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381.","journal-title":"N Engl J Med"},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0948-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:28Z","timestamp":1684618888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0948-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0948-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"12 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HG\u2014Amgen: consultancy, research funding; Novartis: honoraria, research funding; ArtTempi: honoraria; Janssen: consultancy, honoraria, research funding; Sanofi: consultancy, research funding; Mundipharma: research funding; Takeda: consultancy, research funding; Celgene: consultancy, honoraria, research funding; Bristol-Myers Squibb: consultancy, honoraria, research funding; Adaptive Biotechnology: consultancy; Chugai: honoraria, research funding. MAB\u2014Takeda: consultancy, honoraria; Novartis: consultancy, research funding. Travel support: Celgene, Amgen, and Janssen. M-SB: Celgene: consultancy, honoraria; Novartis: consultancy, honoraria, research funding; BMS: consultancy, honoraria, research funding; Amgen: consultancy, honoraria, research funding. JH\u2014Janssen: honoraria, advisory board; Amgen: advisory board; BMS: honoraria, advisory board, research funding; Oncotracker: advisory board; Adaptive Biotech: advisory board; GSK: advisory board. Celgene: consultancy, honoraria, Other: advisory board, research funding. CM-T\u2014research funding: Pfizer, Daiichi Sankyo, BiolineRx, Bayer; advisory boards: Pfizer, Janssen. MS-H\u2014consultancy: Celgene; financial support of educational meetings: Janssen, Takeda, Novartis, Pfizer, Roche, Vifor, Celgene. PR\u2014Honoraria: Takeda, BMS, Roche, Celgene, Sanofi-Aventis; travel support: Celgene, Takeda, Abbvie. UG\u2014honoraria: Sirtex, Daiichi Sankyo, Boehringer Ingelheim, Amgen, Servier, AstraZeneca; consultancy, advisory boards: Merck, BMS, Hexal, Amgen, Celgene, Johnson & Johnson, MSD; travel support: Merck, Amgen, Boehringer Ingelheim. RF\u2014Takeda: honoraria; Bristol-Meyers Squibb: honoraria, Other: travel grant; Celgene: honoraria, Other: travel grant, research funding; Janssen: honoraria; Amgen: honoraria. MH\u2014Novartis: honoraria; Roche: honoraria; Amgen: honoraria; Takeda: honoraria. CS\u2014Novartis: honoraria, research funding; Takeda: honoraria, research funding; Janssen: honoraria, research funding; Celgene: honoraria; BMS: honoraria; Amgen: honoraria; GSK: honoraria. AN\u2014honoraria: Celgene, Takeda, Amgen, Alexion, Sanofi, Janssen, BMS. Research funding: Celgene, Janssen, Takeda. Travel support: Celgene, Takeda, Alexion. HS\u2014Celgene: honoraria, Other: travel suppport, research funding; Janssen: honoraria, Other: travel support, research funding; Novartis: honoraria, Other: travel suppport, research funding; Takeda: honoraria; Amgen: honoraria, Other: travel suppport, research funding; Bristol-Myers Squibb: honoraria, Other: travel suppport, research funding. BB\u2014Janssen: honoraria. KW\u2014Amgen, Celgene, Janssen, and Sanofi: research funding; Amgen, BMS, Celgene, Janssen, Takeda, Adaptive Biotech: honoraria; Amgen, Adaptive Biotech, BMS, Celgene, Janssen, Juno, Sanofi, GSK, Karyopharm and Takeda: consultancy, membership on an entity\u2019s Board of Directors or advisory committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}